Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Clinical trials in gastroenterology bring cutting edge care to patients in the clinic. Researchers in the Translational Gastroenterology Unit look at individual targets of treatment, and also at specific timing of treatment with the aim to change the pattern of chronic life-long disease such as ulcerative colitis or Crohn's disease.

Q: Why do you conduct clinical trials in inflammatory bowel disease?

ST: Inflammatory bowel disease is about Crohn's and ulcerative colitis. It's about bringing tomorrow's treatment to patients today. It's about translating science into clinical practice, and for me at the John Radcliffe it's about bringing the cutting edge care to our patients in the clinic.

Q: Do those clinical trials show promising results?

ST: Certainly. There have been a host of new monoclonal antibodies which are effective for treating diseases which would otherwise be medically untreatable. But there are also studies which are looking at the strategy and approaches to treatment which will alter the pattern of disease in the long term and that's our goal.

Q: Can you give us an example?

ST: There's a very good one which is called the CALM study which we're contributing to in Oxford. This is looking at conventional stepped care with a monoclonal antibody called adalimumab. It is examining tight disease control against conventional clinical symptom disease control. The outcome in two years will, I hope, show a reduction in hospitalisation, surgery, and improved quality of life for patients.

Q: What are the most important lines of research that have developed over the past 5 or 10 years?

ST: I think they are two-fold. The first is the individual targets of treatment. There's a host of cell-signalling molecules which we now have antibodies against, or can use to deliver treatment, so individual targets is one component. But we're not going to change the pattern of chronic life-long disease like ulcerative colitis or Crohn's disease with those sorts of treatments. I think we need therefore a set of strategy studies that can be used to look at all aspects of patient care. In a chronic disease you need this specific timing of treatment so you know where drugs play in the therapeutic armamentarium.

Q: Why does your line of research matter, why should we put money into it?

ST: Inflammatory bowel disease, Cronh's and ulcerative colitis are the epidemics of the future. Around 1% of people in the UK and in Europe have IBD. It's expanding in East Asia, in South America and in the Gulf; if 1% of the population in those countries get IBD then we have a health problem and that's why it matters.

Q: How does your research fit into translational medicine within the department?

ST: In many ways. We've integrated the basic science and the clinical practice at the John Radcliffe which is a really exciting area for gastroenterology. Inflammation underpins carcinogenesis; it interacts with the delivery of care and the new models for delivering care. But also from an NDM perspective with an international component, then part of my role as president of the European Crohn's and Colitis Association representing 31 countries in Europe; also interacting with China, Japan, Korea who've just formed the Asian organisation of Crohn's and Colitis. NDM have an active program in the Far East and also in South America and in the Gulf states and that will bring research fellows and give a profile for Oxford Gastroenterology abroad.

Simon Travis

Before translating basic research into the clinic it is important first to undergo clinical trials in order to identify safe treatments and therapies for disease. Led by Prof Simon Travis, the Gastroenterology Clinical Trials Facility at Oxford University works to translate basic research into clinical trials of novel therapies for gastrointestinal and liver diseases.

Oxford Translational Gastroenterology Unit's logo

More podcasts related to Translational & Clinical

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Jens Rittscher: Biological imaging

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.

Sebastian Nijman: Pharmacogenomics

In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.

Ian Pavord: Asthma

Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.

Trudie Lang: The Global Health Network

The Global Health Network is a successful and growing online science park comprised of varied research communities for different health research groups and cross-cutting health topics. It is built for the research and wider health community by researchers and public health practitioners themselves. It is a trusted source of quality information, education and research tools.

Najib Rahman: Respiratory Medicine

Respiratory medicine encompasses a large number of common diseases like pneumonia, asthma, emphysema and lung cancer. Outcomes are currently relatively poor and the area of research is underfunded. Recent progress have been made towards personalising treatment, and Dr Rahman's research aims at improving patient care.

Chris O’Callaghan: Atherosclerosis & immunity

Atherosclerosis is the most important cause of death worldwide. It is caused by the accumulation of both fatty material and immune cells. Over time, these set up an inflammatory reaction which causes a lot of damage to the blood vessel wall. Although we do have good therapies designed to lower the levels of fatty material, we haven’t any therapies specifically designed to target the effect of the immune system. Professor O'Callaghan's group is working towards developing such therapies.

Stefan Knapp: Development of chemical probes

While drugs were initially developped by testing natural products directly in humans, the current approach is to use chemical probes. These are small chemical coumpounds that inhibit selected targets, avoiding side effects. Professor Knapp produces structures of molecular targets and makes them widely available. This will allow a faster and more cost effective development of new drugs.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.